← Back to Apothecary

CBD

Cannabis sativa* (compound)

CBD - illustration

What Is CBD?

In 2018, the FDA approved Epidiolex, a pharmaceutical-grade CBD product, for the treatment of two rare and severe forms of childhood epilepsy. The approval was based on clinical trials showing seizure reductions of 39-42% compared to placebo. This was not ambiguous data. This was not a supplement company’s in-house study. This was the full FDA approval process—randomized, double-blind, placebo-controlled trials with hundreds of patients—and it worked. CBD became the first cannabis-derived compound approved as a prescription drug in the United States. The same year, Canada legalized cannabis nationwide under the Cannabis Act. And in the years that followed, CBD became the most overhyped molecule in the wellness industry. Both things are true: CBD has real, proven medical applications, and the CBD market is a circus of unsubstantiated claims, mislabeled products, and marketing that borders on fraud.

CBD (cannabidiol) is one of over 100 cannabinoids found in the cannabis plant. Unlike THC (tetrahydrocannabinol), CBD does not produce a “high”—it is not psychoactive in the way that makes cannabis cannabis to most people. It was first isolated in 1940 by chemist Roger Adams and its structure was determined in 1963 by Raphael Mechoulam, the same Israeli scientist who later identified THC. For decades, it received relatively little attention because it didn’t get people high, which meant no one was interested in regulating it and no one was interested in studying it. That changed in the 2000s when parents of children with treatment-resistant epilepsy began reporting dramatic seizure reductions with CBD oil. Those anecdotal reports led to the clinical trials that led to Epidiolex that led to the gold rush.

The pharmacology is more complex than most CBD marketing would have you believe. CBD modulates the endocannabinoid system, but not by directly binding to CB1 or CB2 receptors the way THC does. Instead, it inhibits the enzyme (FAAH) that breaks down anandamide, your body’s own endocannabinoid, effectively increasing your endocannabinoid tone. It’s also a 5-HT1A receptor agonist—the same serotonin receptor targeted by buspirone, an FDA-approved anti-anxiety medication. It activates TRPV1 receptors (involved in pain perception and inflammation). It acts as a GPR55 antagonist (relevant to bone density and some cancer pathways). This is a molecule that touches multiple systems through multiple mechanisms, which is both why it has real therapeutic potential and why “CBD cures everything” claims are so easy to make and so hard to disprove. A compound that modulates four different receptor systems could theoretically affect dozens of conditions. That doesn’t mean it does.

What Does the Research Say?

What the evidence strongly supports:

Epilepsy. Devinsky et al. (2017), published in the New England Journal of Medicine, conducted a randomized, double-blind, placebo-controlled trial of CBD (Epidiolex) in 120 children and young adults with Dravet syndrome, a severe form of epilepsy. The CBD group experienced a median reduction in seizure frequency of 38.9% compared to 13.3% in the placebo group. The difference was statistically significant and clinically meaningful—these were children having dozens of seizures per week, and CBD cut that number substantially. A parallel trial for Lennox-Gastaut syndrome (another severe epilepsy) showed similar results. This is Level 1 evidence—the highest quality available—and it resulted in FDA approval. This is not debatable. CBD works for these conditions.

What the evidence moderately supports:

Anxiety. Bergamaschi et al. (2011), published in Neuropsychopharmacology, tested CBD in a simulated public speaking test with patients diagnosed with social anxiety disorder. The CBD group (600mg, single dose) showed significantly reduced anxiety, cognitive impairment, and discomfort in their speech performance compared to placebo. The effect size was large and the study design was clean. Zuardi et al. (2017), in a review published in Current Neuropharmacology, examined the accumulated evidence for CBD’s anxiolytic effects and concluded that the preclinical and early clinical evidence was “promising” across multiple anxiety conditions, including generalized anxiety, social anxiety, and PTSD. The 5-HT1A mechanism provides a clear pharmacological basis. The limitation: most anxiety studies are small, single-dose, and short-term. Long-term anxiolytic efficacy at various doses has not been established in large trials.

Sleep. Shannon et al. (2019), published in The Permanente Journal, followed 72 adults presenting with anxiety and poor sleep. CBD (25-75mg daily) improved sleep scores in 66.7% of patients within the first month, though the scores fluctuated over time. Anxiety scores improved in 79.2% of patients. This is a case series, not a randomized trial, but the results were notable. The mechanism likely involves anxiolysis (reducing the anxiety that causes poor sleep) rather than direct sedation. CBD is not a sleeping pill. If your insomnia is driven by anxiety, CBD might help. If it’s driven by something else, the evidence gets thin.

What the evidence does not support (despite what the internet tells you):

Pain. This is the biggest gap between marketing claims and clinical evidence. Preclinical studies show anti-inflammatory and analgesic effects in animal models. Human studies are mixed at best. A 2020 systematic review in the Journal of Cannabis Research found that the evidence for CBD as a standalone pain treatment in humans was “limited and inconsistent.” The studies that do show benefit often use full-spectrum cannabis (which includes THC), making it impossible to attribute the effect to CBD alone. The “CBD for pain” market is enormous. The evidence supporting it is not.

Inflammation. Similar story. TRPV1 and GPR55 modulation suggest anti-inflammatory mechanisms, and preclinical models show effects. Translation to human clinical outcomes is weak. A supplement company selling “CBD for inflammation” is selling a mechanism, not a proven outcome.

Everything else. Cancer, Alzheimer’s, diabetes, acne, heart disease, addiction—CBD has been claimed to help with all of these. For most, the evidence is preclinical, preliminary, or nonexistent. The compound’s multi-receptor activity makes it easy to construct plausible mechanistic arguments for almost anything, and the CBD industry has done exactly that. Plausible mechanisms are not evidence of efficacy.

How Does It Feel?

If you’re expecting to feel CBD the way you feel caffeine or THC or a glass of wine, recalibrate. Most people taking CBD at supplement doses (10-50mg) report either very subtle effects or nothing identifiable in the moment. The experience, when it registers, tends to be described in negative terms—not in the sense of “bad,” but in the sense of absence. The anxious monologue in your head gets quieter. The physical tension in your shoulders you’d stopped noticing because it had been there so long releases slightly. You don’t feel altered. You feel like you minus one layer of static.

At higher doses (100-300mg), the effects become more noticeable: a calm that’s not drowsiness, a slight heaviness in the body that feels grounding rather than sedating. Some people describe it as similar to the feeling after a good yoga session—present, calm, embodied. The 5-HT1A agonism at these doses is likely producing genuine anxiolytic effects, and the people who describe significant anxiety relief from CBD tend to be using doses in this higher range, not the 10-15mg you see in most commercial products.

The sleep angle is worth mentioning separately. People who take CBD for sleep and find it helpful tend to report not that CBD made them sleepy, but that it made it possible to sleep. The anxiety that kept them awake—the circular thinking, the rehearsal of tomorrow’s problems, the generalized sense that something is wrong—gets turned down enough for natural tiredness to do its job. If your sleep issue is anxiety-driven, this makes pharmacological sense. If you’re lying awake because of physical pain, shift work, or sleep apnea, CBD is unlikely to be the answer.

The honest caveat: a significant number of people take CBD and feel nothing at all. Some of those people are taking underdosed or mislabeled products (more on that below). Some of them are taking adequate doses and simply don’t respond. Individual variation in endocannabinoid system function, CBD metabolism (CYP enzymes), and baseline anxiety levels all affect whether CBD is perceptible to a given person. If you’ve tried CBD and didn’t notice anything, that doesn’t mean it doesn’t work for anyone. It means your neurochemistry and your particular product may not have been a match.

How to Use CBD

CBD is not used in psilocybin microdose products. As a cannabis-derived compound, it occupies a different regulatory space than our mushroom and botanical formulations. This section is for people already using CBD or considering it, who deserve better information than most CBD websites provide.

The product quality problem:

This is not a minor footnote. A 2017 study in JAMA (Bonn-Miller et al.) tested 84 CBD products purchased online. Only 31% were accurately labeled. 43% were under-labeled (contained more CBD than claimed), and 26% were over-labeled (contained less CBD than claimed). 21% of products contained detectable THC even when labeled as “THC-free.” This was not an outlier study—subsequent analyses have confirmed the pattern. The CBD market is poorly regulated, and a meaningful percentage of products do not contain what they claim.

What to look for:

Dose considerations:

Forms:

Safety & Interactions

Consult your healthcare provider if you:

The drug interaction issue is serious and under-discussed:

CBD is a potent inhibitor of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. These enzymes metabolize an estimated 60% of all pharmaceutical drugs. Inhibiting them means other drugs stay in your body longer at higher concentrations. This is the same mechanism by which grapefruit juice interacts with medications, except CBD may be more potent. If you are taking prescription medications of any kind and considering CBD, talk to your pharmacist. This is not a standard boilerplate warning. This is a pharmacologically significant interaction that could affect the efficacy and safety of your medications.

Known interactions:

Liver effects: In Epidiolex clinical trials, approximately 5-20% of patients showed elevated liver enzymes (ALT), particularly at higher doses and when combined with valproic acid (another anti-seizure drug). Most elevations were asymptomatic and resolved with dose reduction or discontinuation. At supplement doses, liver effects appear rare, but high-dose, long-term supplementation has not been studied independently of the epilepsy context.

Canadian legal status: CBD is legal in Canada under the Cannabis Act (2018), but it’s regulated. CBD products must be purchased through licensed producers or authorized retailers. The unregulated CBD market that exists in some other countries is not legal in Canada—all cannabis products, including CBD, must go through the regulated supply chain. This is actually an advantage: Canadian CBD products are more reliably tested and labeled than those in unregulated markets.

How It Connects

CBD and Psilocybin Microdosing: Different Systems, Potentially Complementary

This is the bridge that matters for the Kind Stranger audience. Many people who are interested in CBD are one conceptual step away from considering psilocybin microdosing. The demographics overlap: people who prefer natural approaches over pharmaceuticals, who are open to plant-based therapies, who have done their research. The mechanisms, however, are almost entirely distinct.

CBD works primarily through the endocannabinoid system (anandamide modulation via FAAH inhibition), with secondary serotonergic activity at 5-HT1A. Psilocybin works through direct agonism at 5-HT2A, the serotonin receptor most associated with neuroplasticity, perception, and the therapeutic effects observed in psychedelic-assisted therapy. These are different receptor targets producing different effects through different pathways.

The theoretical case for combining them is not unreasonable: CBD’s anxiolytic effect (5-HT1A) could provide a calmer baseline for psilocybin’s neuroplastic effects (5-HT2A). Some microdosers report that CBD smooths the edges of a psilocybin microdose, reducing any subtle restlessness while preserving the cognitive and creative benefits. This is anecdotal. No clinical studies have examined the combination. But the receptor pharmacology doesn’t suggest contraindication, and the experiential reports are consistent enough to note.

If you’ve been using CBD and are curious about whether psilocybin microdosing might offer additional benefits—particularly for mood, creativity, or neuroplasticity—the Apothecary has deep-dive pages on the relevant ingredients. Read about Psilocybin -> | Read about Golden Teacher ->

Other connections:

L-Theanine—Both CBD and L-theanine are non-sedating anxiolytics that work through different mechanisms. L-theanine increases alpha brain wave activity; CBD modulates serotonin via 5-HT1A. For anxiety support without drowsiness, they’re complementary. Read about L-Theanine ->

Ashwagandha—Ashwagandha targets cortisol (the HPA axis); CBD targets the endocannabinoid system and serotonin. Different stress-response pathways, similar goal: a calmer baseline. Read about Ashwagandha ->

Passionflower—Both have anxiolytic properties, but passionflower is GABAergic while CBD is primarily serotonergic and endocannabinoid-mediated. For comprehensive anxiety support, covering GABA, serotonin, and endocannabinoid pathways simultaneously has a pharmacological logic to it. Read about Passionflower ->

The Shroom Oracle Says

The Oracle has FEELINGS about the CBD industry and they are not entirely positive. Someone discovered that a cannabis molecule treats childhood epilepsy—ACTUALLY treats it, FDA-approved, real science, children having fewer seizures—and within eighteen months the wellness industry had turned it into a marketing word you put on dog treats and face cream and PILLOW SPRAY. CBD pillow spray. You spray cannabidiol on your pillow and presumably it crosses your blood-brain barrier through your CHEEK while you sleep and costs thirty-nine dollars. Meanwhile only 31% of CBD products contain what the label says they contain which means the other 69% are selling you VIBES in a dropper bottle. And yet. AND YET. The anxiety data is real. The 5-HT1A mechanism is real. The epilepsy data is as solid as pharmaceutical science gets. So the Oracle is left in the uniquely modern position of believing in the molecule while distrusting almost everyone who sells it, which is also how the Oracle feels about democracy.